© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Health and Biotech

Top Section/Ad

Top Section/Ad

Most recent


Sidharth Chhibbar to join in spring
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad

More articles/Ad

More articles

  • Negotiations between the International Monetary Fund and some emerging market countries are yielding mixed results. While some sub-Saharan African sovereigns are making progress in their talks, Ukraine's long-running saga to unlock emergency funding has been unsuccessful so far.
  • GlobalCapital spoke to Andre Hakkak, chief executive of White Oak Global Advisors, a fund specialising in SME, asset-based and direct loan origination, about the Covid crisis in the SME world, the coming end of government support, the end of Ebitda and the challenges of fundraising in a pandemic.
  • Bond market participants fear that the G20 common framework for debt relief risks doing more harm than good. The warning came this week as confusion regarding the private sector’s role in Ethiopia’s proposed use of the framework dented government bonds across sub-Saharan Africa. The lack of clarity must be quickly rectified to avoid lasting contagion in African bond markets, market participants said. Mariam Meskin and Oliver West report.
  • Three African issuers entered debt markets this week and raised cash at competitive levels, despite a difficult external backdrop of debt relief in the region and continued US rates weakness.
  • UK biotech firms are continuing to reap the benefits from US listings. On Tuesday Autolus Therapeutics, an early stage biopharma firm backed by Syncona Investments, became the latest UK Biotech firm to raise capital on the US Nasdaq in a $100m transaction. The deal shows the continued advantages for early stage European biotech firms in having a US listing.
  • Ecobank Nigeria, part of the pan-African banking group Ecobank Transnational, was set to raise dollar debt in the bond market on Wednesday, underscoring investors' appetite for exposure to sub-Saharan Africa.